Characterization of the serotonin 2A receptor selective PET tracer (R)-[<sup>18</sup>F]MH.MZ in the human brain.

Kramer, Vasko; Dyssegaard, Agnete; Flores, Jonathan; Soza-Ried, Cristian; Rösch, Frank; Knudsen, Gitte Moos; Amaral, Horacio; Herth, Matthias M · Eur J Nucl Med Mol Imaging · 2020

prospective_cohort · Level II

Where this comes from

Abstract

The serotonin receptor subtype 2A antagonist (5-HT<sub>2A</sub>R) (R)-[<sup>18</sup>F]MH.MZ has in preclinical studies been identified as a promising PET imaging agent for quantification of cerebral 5-HT<sub>2A</sub>Rs. It displays a very similar selectivity profile as [<sup>11</sup>C]MDL 100907, one of the most selective compounds identified thus far for the 5-HT<sub>2A</sub>R. As [<sup>11</sup>C]MDL 100907, (R)-[<sup>18</sup>F]MH.MZ also displays slow brain kinetics in various animal models; however, the half-life of fluorine-18 allows for long scan times and consequently, a more precise determination of 5-HT<sub>2A</sub>R binding could still be feasible. In this study, we aimed to evaluate the potential of (R)-[<sup>18</sup>F]MH.MZ PET to image and quantify the 5-HT<sub>2A</sub>R in the human brain in vivo. Nine healthy volunteers underwent (R)-[<sup>18</sup>F]MH.MZ PET at baseline and four out of these also received a second PET scan, after ketanserin pretreatment. Regional time-activity curves of 17 brain regions were analyzed before and after pretreatment. We also investigated radiometabolism, time-dependent stability of outcomes measures, specificity of (R)-[<sup>18</sup>F]MH.MZ 5-HT<sub>2A</sub>R binding, and performance of different kinetic modeling approaches. Highest uptake was determined in 5-HT<sub>2A</sub>R rich regions with a BP<sub>ND</sub> of approximately 1.5 in cortex regions. No radiometabolism was observed. 1TCM and 2TCM resulted in similar outcome measure, whereas reference tissue models resulted in a small, but predictable bias. (R)-[<sup>18</sup>F]MH.MZ binding conformed to the known distribution of 5-HT<sub>2A</sub>R and could be blocked by pretreatment with ketanserin. Moreover, outcomes measures were stable after 100-110 min. (R)-[<sup>18</sup>F]MH.MZ is a suitable PET tracer to image and quantify the 5-HT<sub>2A</sub>R system in humans. In comparison with [<sup>11</sup>C]MDL 100907, faster and more precise outcome measure could be obtained using (R)-[<sup>18</sup>F]MH.MZ. We believe that (R)-[<sup>18</sup>F]MH.MZ has the potential to become the antagonist radiotracer of choice to investigate the human 5-HT<sub>2A</sub>R system.

Medical subject headings